BioLife Solutions (BLFS) Prices 5.18M Share Common Stock Offering at $14.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St tumbles as hot CPI boosts rate-hike bets; banks, AI stocks weigh
- Oil prices steady after gains on Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock
July 2, 2020 7:41 AM EDTBOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife,... More
BioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020
July 1, 2020 4:02 PM EDTBOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for the second quarter of 2020 of $9.6 million to $9.8 million, representing 43% to 46% growth over the same quarter in 2019.
... More
BioLife Solutions Announces Proposed Public Offering of Common Stock
July 1, 2020 4:01 PM EDTBOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. In addition,... More



